IMAX Achieves Record $61.3 Million During Chinese New Year

IMAX Corporation has reported a record-breaking box office performance during the Chinese New Year period, amassing $61.3 million in ticket sales. This figure represents a 72% increase compared to the same period in the previous year, underscoring a significant resurgence in the Chinese cinema market.

Leading this impressive performance was “The Wandering Earth 2,” which has become IMAX’s highest-grossing local language film to date. The film generated $50.4 million on IMAX screens across China, accounting for 9% of its total box office revenue, despite IMAX screens comprising less than 1% of the total available. This achievement also places “The Wandering Earth 2” as IMAX’s third highest-grossing release ever in the Chinese market.

IMAX CEO Rich Gelfond highlighted the importance of these results, stating that the Chinese box office is experiencing a robust recovery. He emphasized that, just two months into 2023, IMAX has delivered record-breaking results with its Chinese New Year slate and has seen a strong performance in China for “Avatar: The Way of Water,” with a promising lineup of Hollywood films yet to come. Gelfond noted that with China reemerging as a leading moviegoing market, IMAX is making significant strides toward returning to pre-pandemic levels of global box office performance.

Since fully reopening in December, China’s box office has demonstrated a remarkable comeback, more than doubling North American box office figures for January. Up to February 16, IMAX has generated $82 million in the Chinese market for 2023, already surpassing half of the $152.5 million earned throughout 2022. A significant contributor to this success is James Cameron’s “Avatar: The Way of Water,” which has earned over $52 million in China since its December 16 release, making it only the third film to surpass the $50 million mark in the country.

The diverse Chinese New Year slate also included Zhang Yimou’s period drama “Full River Red,” animated film “Deep Sea” produced by Enlight Film, and espionage thriller “Hidden Blade” produced by Bona Film and Xiyue Film. Daniel Manwaring, CEO of IMAX China, expressed optimism for the future, stating that the excellent slate of Chinese New Year films provides a great springboard for the year ahead. He congratulated Chinese studio and filmmaking partners for reigniting the country’s passion for moviegoing and looked forward to more successes in 2023.

In the coming weeks, several high-profile Hollywood releases are set to debut across the IMAX China network, including Disney/Marvel’s “Ant-Man and the Wasp: Quantumania,” Warner Bros./DC’s “Shazam! Fury of the Gods,” and Paramount’s “Dungeons and Dragons: Honor Among Thieves.” These releases are anticipated to further bolster IMAX’s performance in the Chinese market.

Analyst firm Benchmark has also noted IMAX’s strong position, suggesting that the company is poised to benefit from a robust 2025 box office, despite some underperforming major releases in late 2024. Benchmark analyst Mike Hickey acknowledged a softer-than-expected box office but viewed the resulting share-price weakness as a buying opportunity. He emphasized confidence in the company’s growth prospects, highlighting the importance of a rebounding IMAX China box office. Hickey expressed optimism that the Chinese New Year, beginning January 29, would kickstart the recovery, though he noted that the durability and magnitude of the rebound beyond the holiday remain uncertain.

China is positioned for significant growth in 2025, with the Chinese New Year slate featuring promising titles like “Creation of the Gods II,” “Ne Zha 2,” “Detective Chinatown,” and “Legend of the Condor Heroes,” expected to drive strong box-office performance. Upcoming Hollywood blockbusters such as “Mission: Impossible – Dead Reckoning Part Two,” “Avatar 3,” “Formula 1,” and “Zootopia 2” are also anticipated to bolster 2025 prospects. IMAX China’s strong ties to the film bureau are expected to enable Hollywood releases with minimal cuts, further enhancing the company’s outlook.